Metzger Michael A's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Oct 27, 2021
- Accession no.
- 0001562180-21-006652
- Filed
- Oct 27, 2021
- Trade date
- Oct 25-26, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.17M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metzger Michael ACIK 0001507220 | Director, Officer (President and COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2021 | Common Stock | MOption exerciseAcquired | +44,704 | $7.20 | +$321,868.8 | 62,363 | Direct | |
| Oct 25, 2021 | Common Stock | SSaleDisposed | −44,704 | $19.13F2 | −$855,187.52 | 17,659 | Direct | |
| Oct 26, 2021 | Common Stock | MOption exerciseAcquired | +16,296 | $7.20 | +$117,331.2 | 33,955 | Direct | |
| Oct 26, 2021 | Common Stock | SSaleDisposed | −16,296 | $19.20F3 | −$312,883.2 | 17,659 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2021 | Common Stock | MOption exerciseDisposed | −44,704 | $0.00 | $0 | 0 | Direct | |
| Oct 26, 2021 | Common Stock | MOption exerciseDisposed | −16,296 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The share price ranged from $19.00 to $19.48
Referenced by the price of 1 transaction in Table I.
- F3
The sales price ranged from $19.01 to $19.33
Referenced by the price of 1 transaction in Table I.